Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity acrossFGFR2Alterations and Resistance Mutations
Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, et al.
Cancer Discovery (2023) Vol. 13, Iss. 9, pp. 2012-2031
Open Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

Artificial Intelligence for Drug Discovery: Are We There Yet?
Catrin Hasselgren, Tudor I. Oprea
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 527-550
Open Access | Times Cited: 74
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 56
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2
Heike Schönherr, Pelin Ayaz, Alexander M. Taylor, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 6
Open Access | Times Cited: 21
The evolving landscape of tissue‐agnostic therapies in precision oncology
Vivek Subbiah, Mohamed A. Gouda, Bettina Ryll, et al.
CA A Cancer Journal for Clinicians (2024) Vol. 74, Iss. 5, pp. 433-452
Open Access | Times Cited: 19
Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial
Jordi Rodón, Silvia Damian, Muhammad Furqan, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1645-1654
Open Access | Times Cited: 17
Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
Qibiao Wu, Haley Ellis, Giulia Siravegna, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 1, pp. 198-208
Open Access | Times Cited: 31
Targeting FGFR for cancer therapy
Pei Zhang, Lin Yue, Qingqing Leng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 13
Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers
Khine Shan, Shivani Dalal, Nyein Nyein Thaw Dar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 849-849
Open Access | Times Cited: 11
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies
Alessandro Parisi, Blandine Delaunay, Giada Pinterpe, et al.
European Journal of Cancer (2024) Vol. 200, pp. 113587-113587
Open Access | Times Cited: 9
Understanding and Overcoming Resistance to Selective FGFR inhibitors Across FGFR2-Driven Malignancies
Francesco Facchinetti, Yohann Loriot, Floriane Brayé, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 21, pp. 4943-4956
Open Access | Times Cited: 6
Exploring FGFR signaling inhibition as a promising approach in breast cancer treatment
Yan Peng, Pengfei Zhang, Wuxuan Mei, et al.
International Journal of Biological Macromolecules (2024) Vol. 267, pp. 131524-131524
Closed Access | Times Cited: 5
Current Status of Computational Approaches for Small Molecule Drug Discovery
Weijun Xu
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 21, pp. 18633-18636
Open Access | Times Cited: 5
Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts’ position paper
Matteo Fassan, Valentina Angerilli, Nicola Normanno, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 194, pp. 104224-104224
Open Access | Times Cited: 5
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors
Benjamin Garmezy, Mitesh J. Borad, Rastilav Bahleda, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 4, pp. 1165-1173
Open Access | Times Cited: 5
Alchemical Transformations and Beyond: Recent Advances and Real-World Applications of Free Energy Calculations in Drug Discovery
Runtong Qian, Jing Xue, You Xu, et al.
Journal of Chemical Information and Modeling (2024) Vol. 64, Iss. 19, pp. 7214-7237
Closed Access | Times Cited: 5
FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma
Yuanli Zhen, Kai Liu, Lei Shi, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer
Lewis Au, J. Collin, John M. Mariadason
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1117-1117
Open Access | Times Cited: 4
Discovery of Pyrrolopyrazine Carboxamide Derivatives as Potent and Selective FGFR2/3 Inhibitors that Overcome Mutant Resistance
Yazhou Wang, Yihong Zhang, Jinxin Liu, et al.
Journal of Medicinal Chemistry (2025) Vol. 68, Iss. 3, pp. 3886-3899
Closed Access
Discovery of BW710 as a Potent, Selective and Orally Bioavailable Fibroblast Growth Factor Receptor 2 (FGFR2) Inhibitor
Bowen Yang, Qiuju Xun, Yuan Tian, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117339-117339
Closed Access
Update for: New developments in systemic therapy for advanced biliary tract cancer
Chigusa Morizane, Makoto Ueno, Masafumi Ikeda, et al.
Japanese Journal of Clinical Oncology (2025)
Closed Access
S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion
Sabrina Groß, Michael Bitzer, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 02, pp. e82-e158
Closed Access
Current status and prospects of targeted therapy for cholangiocarcinoma based on molecular characteristics
Xiaoqiang Cui, Teng Huang, Tianyi Jiang, et al.
Cancer Letters (2025) Vol. 614, pp. 217540-217540
Closed Access
Resistance to Immunotherapy in Non-small Cell Lung Cancer: Unraveling Causes, Developing Effective Strategies, and Exploring Potential Breakthroughs
Shuang Dong, Xiaoyu Li, Qing Huang, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101215-101215
Closed Access
Pancreatic Ductal Adenocarcinoma (PDAC): Clinical Progress in the Last Five Years
Osama Mosalem, Ahmed Abdelhakeem, Nayef Hikmat Abdel-Razeq, et al.
Expert Opinion on Investigational Drugs (2025), pp. 1-12
Closed Access
Targeting fibroblast growth factor receptor (FGFR) with inhibitors in head and neck cancers: Their roles, mechanisms and challenges
Daowen Luo, Sirinart Kumfu, Nipon Chattipakorn, et al.
Biochemical Pharmacology (2025) Vol. 235, pp. 116845-116845
Closed Access
Page 1 - Next Page

Scroll to top